Related Experiment Video
Updated: Jul 9, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
MMP-2 regulates Src activation via repression of the CHK/MATK tumor suppressor in osteosarcoma
Deanna V Maybee1, Christopher R Cromwell2, Basil P Hubbard2
1Department of Pharmaceutical Sciences, SUNY Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA.
Background:
Doxorubicin, a first-line anticancer drug for osteosarcoma treatment, has been the subject of recent research exploring the mechanisms behind its chemoresistance and its ability to enhance cell migration at sublethal concentrations. Matrix metalloproteinase-2 (MMP-2), a type IV collagenase and zinc-dependent endopeptidase, is well-known for degrading the extracellular matrix and promoting cancer metastasis. Our previous work demonstrated that nuclear MMP-2 regulates ribosomal RNA transcription via histone clipping, thereby controlling gene expression. Additionally, MMP-2 activity is regulated by the non-receptor tyrosine kinase and oncogene, Src, which plays a crucial role in cell adhesion, invasion, and metastasis. Src kinase is primarily regulated by two endogenous inhibitors: C-terminal Src kinase (Csk) and Csk homologous kinase (CHK/MATK).
Aim:
In this study, we reveal that the MMP-2 gene acts as an upstream regulator of Src kinase activity by suppressing its endogenous inhibitor, CHK/MATK, in osteosarcoma cells.
Methods And Results:
We show that enhanced osteosarcoma cell migration which is induced by sublethal concentrations of doxorubicin can be overcome by inactivating the MMP-2 gene or overexpressing CHK/MATK. Our findings highlight the MMP-2 gene as a promising additional target for combating cancer cell migration and metastasis. This is due to its role in suppressing on the gene and protein expression of the tumor suppressor CHK/MATK in osteosarcoma.
Conclusion:
By targeting the MMP-2 gene, we can potentially enhance the effectiveness of doxorubicin treatment and reduce chemoresistance in osteosarcoma.
Insights
Matrix metalloproteinase-2 (MMP-2) suppresses tumor suppressor CHK/MATK, promoting osteosarcoma cell migration. Targeting MMP-2 may enhance doxorubicin treatment effectiveness and reduce chemoresistance by restoring CHK/MATK expression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Doxorubicin is a primary osteosarcoma treatment, but chemoresistance and enhanced cell migration at sublethal doses are concerns.
- Matrix metalloproteinase-2 (MMP-2) degrades extracellular matrix, promoting metastasis, and its nuclear form regulates gene expression.
- Src kinase, crucial for metastasis, is inhibited by Csk and Csk homologous kinase (CHK/MATK).
Purpose of the Study:
- To investigate the role of MMP-2 in regulating Src kinase activity in osteosarcoma.
- To determine if MMP-2 acts as an upstream regulator of Src kinase by affecting its inhibitor, CHK/MATK.
Main Methods:
- Investigated the relationship between MMP-2 and CHK/MATK in osteosarcoma cells.
- Assessed the impact of MMP-2 gene inactivation and CHK/MATK overexpression on doxorubicin-induced cell migration.
Main Results:
- MMP-2 gene acts as an upstream regulator of Src kinase by suppressing CHK/MATK expression in osteosarcoma.
- Inactivating MMP-2 or overexpressing CHK/MATK counteracted doxorubicin-induced osteosarcoma cell migration.
- MMP-2 suppresses both gene and protein expression of the tumor suppressor CHK/MATK.
Conclusions:
- MMP-2 is a key suppressor of CHK/MATK in osteosarcoma, driving cancer cell migration.
- Targeting MMP-2 offers a promising strategy to combat osteosarcoma cell migration and metastasis.
- Inhibiting MMP-2 may enhance doxorubicin efficacy and overcome chemoresistance in osteosarcoma treatment.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Role of Matrix Metalloproteases in Degradation of ECM

